Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

NCT01776411 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Refractory PTCL

Interventions

DRUG: forodesine hydrochloride

Sponsor

Mundipharma K.K.